DOCSLIB.ORG

Indications for Acute and Chronic Digitalis Administration in Heart Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Indications for Acute and Chronic Digitalis Administration in Heart Failure Henry Ford Hospital Medical Journal Volume 34 Number 3 Article 9 9-1986 Indications for Acute and Chronic Digitalis Administration in Heart Failure Mihai Gheorghiade Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Gheorghiade, Mihai (1986) "Indications for Acute and Chronic Digitalis Administration in Heart Failure," Henry Ford Hospital Medical Journal : Vol. 34 : No. 3 , 178-183. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol34/iss3/9 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. Indications for Acute and Chronic Digitalis Administration in Heart Failure Mihai Gheorghiade, MD* lthough digitalis glycosides were introduced for the treat­ in patients having congestive heart failure in both the acute and Ament of cardiac disorders almost 200 years ago, doubt per­ convalescent phases of myocardial infarction yields conflicting sists regarding the role of these inotropic agents in the treatment and inconsistent data (14,15). of heart failure patients with a normal sinus rhythm. Cardiac If digitalis is administered to patients in sinus rhythm during glycosides are undoubtedly highly effective in controlling the the acute phase of myocardial infarction with either absent or ventricular response in the presence of atrial fibrilladon, and mild clinical heart failure, little hemodynamic benefit can be ex­ thereby enhance cardiac performance. Past experimental and pected (16,17). In contrast, digitalis therapy is of value in this clinical data have shown that various digitalis preparations im­ setting when atrial fibrillation is present; benefit is obtained by prove ventricular function when the dmg is acutely administered control ofthe ventricular response to the tachyanhythmia. Digi­ and indices of myocardial contractility are measured (1-3), How­ talis might be of benefit when signs of heart failure are accom­ ever, a dissociation may exist between the effects of digitalis on panied by an S3 gallop, significant cardiomegaly, and elevation indices of ventricular contractility (systolic time intervals, ofthe left ventricular end-diastolic pressure. However, even in measurements of rate of rise of left ventricular pressure, or di­ this setting, few studies in humans are available that suggest rect measurement of myocardial contractile force) and overall a significant improvement in left ventricular performance with cardiac pump performance, which is expressed as the rela­ digitalization (18). Fonesteret al (19), Lipp et al (20), and Gold­ tionship between left ventricular filling pressure and cardiac out­ stein et al (21) reported no occunence of hemodynamic im­ put. Although indices of contractility can be shown to increase provement in their patients, whereas Hodges et al (22) reported with acute administration of digitalis, significantly improved an improvement in only four of the ten patients studied. Rahim- pump performance does not always occur (4-7), toola et al (23) reported an improvement in left ventricular fill­ The clinical use of digitalis should be reexamined for several ing pressure without a significant change in cardiac index when reasons. Concerning the benefit of digitalis, the literature is ouabain was administered within 48 hours of acute myocardial somewhat confusing because authors fail to distinguish acute infarction. In fact, rapid intravenous administration of digi­ and chronic effects of the dmg. Scant information is available talis may be detrimental, which is perhaps related to its acute demonstrating the relative effect of cardiac glycosides compared peripheral constrictor effect (16). to the combination of diuretics and vasodilators in the treatment Infarct size—Varankov and associates (24) examined the of heart failure. A troubling risk of toxicity remains because of effect of acetylstrophanthidin on the rate of creatine phos- the nanow borderline between the therapeutic and toxic effects; phokinase (CK) efflux in 59 patients with acute myocardial in­ toxic manifestations of digitalis therapy still comprise some farction. They found an accelerated release of CK in the plasma of the most prevalent adverse drug reactions encountered in ofthese patients, with an evolving uncomplicated infarction, clinical practice (8). Except for the use of digitalis in atrial and concluded that digitalis administration may have adversely fibrillation, it is uncertain who benefits from digitalis. Cardiac increased infarct size. glycosides purportedly increase mortality when administered Arrhythmogenic effect—Whether patients with myocardial soon after myocardial infarction (9,10). In patients initially infarction are more sensitive to the arrhythmogenic effects of treated with diuretics to maintain dry body weight, no added digitalis has not been definitively ascertained. Reicansky and benefit from digitalis is observed (11). Newer inotropic drugs colleagues (25), using a double-blind randomized protocol, and vasodilators have been shown to be effective in treating found no difference in the incidence of rhythm disturbances be­ heart failure patients and may be superior to digitalis (12), tween digoxin-treated and control padents with acute myocar­ dial infarction. An increased susceptibility to anhythmias in the presence of digitalis intoxication has been observed in experi­ Acute Use of Cardiac Glycosides mental models following acute coronary ligation (26,27), Digitalis in acute myocardial infarction Although digitalis therapy in patients with acute myocardial Submitted for publication: July 31, 1986. Accepted for publication: August 21, 1986. infarction has been employed since 1912 (13), controversy per­ *Hearl and Vascular Institute, Division of Cardiovascular Medicine, Henry Ford sists regarding tbe indications and use of digitalis in such pa­ Hospital. Address correspondence to Dr Gheorghiade, Heart and Vascular Institute, Division of tients. Investigation ofthe effects of digitalis on cardiac function Cardiovascular Medicine, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, Ml 48202. 178 Henry Ford Hosp Med J—Vol 34, No 3, 1986 Digitalis and Heart Failure—Gheorghiade Therapeutic approach—Patients in sinus rhythm with mild to Table 1 moderate heart failure (bibasilar rales, S3 gallop, and upper Maintenance Diuretic and Vasodilator Therapy zone pulmonary venous redistribution on chest roentgenogram) Before and After Digoxin Withdrawal secondary to acute myocardial infarction should receive diuret­ ics alone or a combination of a diuretic and a vasodilator as the No. of Dose first step in their management. Intravenous nitroglycerin or Diuretics/Vasodilators Patients Mean (Range) nitropmsside appears to be highly effective in reducing the left Diuretics: Furosemide 12 55 mg (20 to 80 mg) ventricular end-diastolic pressure and improving cardiac output Hydrochlorothiazide 8 50 mg (25 to 100 mg) in such padents. The addition of digoxin to nitropmsside may Vasodilators: increase the cardiac output more than nitropmsside alone in pa­ Hydralazine 2 93 mg (40 to 200 mg) Isosorbide dinitrate 13 66 mg (40 to 120 mg) tients with heart failure complicating myocardial infarction, but Nitroglycerin ointment 3 2 in (2 to 4 in) it does not produce any further decrease in pulmonary capillary wedge pressure (28). Cardiogenic shock—The beneficial effects of digitalis have dynamic effects of digoxin discontinuation in patients with nor­ been examined in the setting of cardiogenic shock, in which mal sinus rhythm and congestive heart failure (36). We sought to marked hypotension is observed in association with an elevated determine changes not only in symptoms and physical findings left ventricular filling pressure. The prognosis of patients with after discontinuation of the dmg but also in left ventricular func­ cardiogenic shock appears to be unaltered following digitalis tion and exercise capacity. The major difference in our study de­ administration (17). Clinical studies have reported that the dmg sign from that employed in previous studies was to maximize does not appear to have any beneficial effect on left ventricular therapy with diuretics and vasodilator dmgs before discontinu­ function (29-31). Cohn and associates (29) demonstrated thatthe ing digoxin. early pressor effect of intravenously administered ouabain is deleterious in patients with cardiogenic shock. Digitalis adds lit­ Materials tle when compared with the more potent inotropic agents such as The study group patient population was homogeneous in that dobutamine (23). all had documented chronic heart failure secondary to coronary artery disease. Twenty-four consecutive patients were prospec­ tively studied. All 24 patients were men with a mean age of 60 Acute digitalization in patients with chronic heart failure years (range of 42 to 80 years). No patient had a history of atrial Not all padents with severe and chronic heart failure will tachyanhythmia. The indication for initiating long-term digoxin show an improvement in hemodynamics after the administration therapy in the study cohort was the presence of clinical and/or of intravenous digitalis (32-35). Selzerand Malmborg (32) were radiographic evidence of congestive heart failure. None of the unable to predict which patients would respond
Load more

Recommended publications
  • Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis Lanata Leaves
    Pharmacology & Pharmacy, 2016, 7, 200-207 Published Online May 2016 in SciRes. http://www.scirp.org/journal/pp http://dx.doi.org/10.4236/pp.2016.75026 Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis lanata Leaves Yasuhiko Higashi*, Yukari Ikeda, Youichi Fujii Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan Received 21 April 2016; accepted 28 May 2016; published 31 May 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract We previously developed an HPLC method for determination of lanatoside C, digoxin and α-acetyl- digoxin in digitalis glycosides isolated from Digitalis lanata leaves. Here, we present an improved HPLC-UV method to determine those compounds and deslanoside. We used the improved method to examine the effects of various pretreatments on the amounts of the four compounds isolated from the leaves, with the aim of maximizing the yield of digoxin. Leaves were extracted with 50% methanol, followed by clean-up on a Sep-Pak C18 cartridge prior to HPLC analysis. The amounts of lanatoside C, digoxin and α-acetyldigoxin per 100 mg of the leaves without pretreatment were 115.6, 7.45 and 23.8 μg, respectively (deslanoside was not detected). Pretreatment with acetic ac- id, which activated deglucosylation mediated by digilanidase present in the leaves, increased the amounts of digoxin and α-acetyldigoxin, while lanatoside C and deslanoside were not detected. Pretreatment with sodium methoxide, which hydrolyzed lanatoside C to deslanoside, increased the yields of deslanoside and digoxin, while lanatoside C and α-acetyldigoxin were not detected.
    [Show full text]
  • Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/Mtor Signaling Pathways
    biomolecules Article Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways Dhanasekhar Reddy 1 , Ranjith Kumavath 1,* , Preetam Ghosh 2 and Debmalya Barh 3 1 Department of Genomic Science, School of Biological Sciences, Central University of Kerala, Tejaswini Hills, Periya (P.O) Kasaragod 671316, Kerala, India; [email protected] 2 Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA; [email protected] 3 Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur 721172, West Bengal, India; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +91-8547-648-620 Received: 21 October 2019; Accepted: 22 November 2019; Published: 27 November 2019 Abstract: Cardiac glycosides (CGs) are a diverse family of naturally derived compounds having a steroid and glycone moiety in their structures. CG molecules inhibit the α-subunit of ubiquitous transmembrane protein Na+/K+-ATPase and are clinically approved for the treatment of cardiovascular diseases. Recently, the CGs were found to exhibit selective cytotoxic effects against cancer cells, raising interest in their use as anti-cancer molecules. In this current study, we explored the underlying mechanism responsible for the anti-cancer activity of Lanatoside C against breast (MCF-7), lung (A549), and liver (HepG2) cancer cell lines. Using
    [Show full text]
  • Eiichi Kimura, MD, Department of Internal Medicine, Nippon Medical
    Effect of Metildigoxin (ƒÀ-Methyldigoxin) on Congestive Heart Failure as Evaluated by Multiclinical Double Blind Study Eiichi Kimura,* M.D. and Akira SAKUMA,** Ph.D. In Collaboration with Mitsuo Miyahara, M.D. (Sapporo Medi- cal School, Sapporo), Tomohiro Kanazawa, M.D. (Akita Uni- versity School of Medicine, Akita), Masato Hayashi, M.D. (Hiraga General Hospital, Akita), Hirokazu Niitani, M.D. (Showa Uni- versity School of Medicine, Tokyo), Yoshitsugu Nohara, M.D. (Tokyo Medical College, Tokyo), Satoru Murao, M.D. (Faculty of Medicine, University of Tokyo, Tokyo), Kiyoshi Seki, M.D. (Toho University School of Medicine, Tokyo), Michita Kishimoto, M.D. (National Medical Center Hospital, Tokyo), Tsuneaki Sugi- moto, M.D. (Faculty of Medicine, Kanazawa University, Kana- zawa), Masao Takayasu, M.D. (National Kyoto Hospital, Kyoto), Hiroshi Saimyoji, M.D. (Faculty of Medicine, Kyoto University, Kyoto), Yasuharu Nimura, M.D. (Medical School, Osaka Uni- versity, Osaka), Tatsuya Tomomatsu, M.D. (Kobe University, School of Medicine, Kobe), and Junichi Mise, M.D. (Yamaguchi University, School of Medicine, Ube). SUMMARY The efficacy on congestive heart failure of metildigoxin (ƒÀ-methyl- digoxin, MD), a derivative of digoxin (DX), which had a good absorp- tion rate from digestive tract, was examined in a double blind study using a group comparison method. After achieving digitalization with oral MD or intravenous deslanoside in the non-blind manner, mainte- nance treatment was initiated and the effects of orally administered MD and DX were compared. MD was administered in 44 cases , DX in 42. The usefulness of the drug was evaluated after 2 weeks , taking into account the condition of the patient and the ease of administration .
    [Show full text]
  • Radioimmunoassay
    Radioimmunoassay Measurement of Serum Cardiac Glycoside Levels: Using Pharmacologic Principles to Solve Crossreactivity Problems Thomas J. Persoon The University of Iowa, Iowa City, Iowa Laboratories performing analyses for serum cardiac Results glycosides are sometimes faced with the problem of dis­ Data collected in our laboratory are similar to those tinguishing between digoxin and digitoxin in a specimen. published by Kuno-Sakai. Tables 3 and 4 show the The antibodies to the cardiac glycosides supplied with measured concentrations of digoxin and digitoxin from radioimmunoassay kits for these drugs have some patient sera known to contain only one drug. Figure 1 measurable degree of cross reactivity. Therapeutic levels is a plot of measured digoxin levels versus actual of digitoxin are approximately ten times greater than digitoxin concentration of serum digitoxin standards. those of digoxin, and the half-lives of these drugs in The slope and intercept of the line were determined by serum differ by a factor of four. These facts have been the linear least-squares technique. combined into a series of rules which allow the technologist to distinguish between digoxin and digitoxin Discussion in a sample and provide a level of the drug that has been corrected for crossreactivity. Figure 2 shows the chemical structures of four cardiac glycosides: digoxin, digitoxin, cedilanid, and In 1972 Edmonds et al. ( 1) published data on the crossreactivity of digitoxin in the digoxin radioim­ TABLE 1. Crossreactivity of Digitoxin in Digoxin RIA munoassay (Tables 1 and 2). They showed the slopes Measured level of of digoxin-digitoxin cross reactivity plots to be linear. Digitoxin added (ng/mll digoxin (ng/mll Kuno-Sakai et al.
    [Show full text]
  • Quo Vadis Cardiac Glycoside Research?
    toxins Review Quo vadis Cardiac Glycoside Research? Jiˇrí Bejˇcek 1, Michal Jurášek 2 , VojtˇechSpiwok 1 and Silvie Rimpelová 1,* 1 Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, Prague 6, Czech Republic; [email protected] (J.B.); [email protected] (V.S.) 2 Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 3, Prague 6, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +420-220-444-360 Abstract: AbstractCardiac glycosides (CGs), toxins well-known for numerous human and cattle poisoning, are natural compounds, the biosynthesis of which occurs in various plants and animals as a self-protective mechanism to prevent grazing and predation. Interestingly, some insect species can take advantage of the CG’s toxicity and by absorbing them, they are also protected from predation. The mechanism of action of CG’s toxicity is inhibition of Na+/K+-ATPase (the sodium-potassium pump, NKA), which disrupts the ionic homeostasis leading to elevated Ca2+ concentration resulting in cell death. Thus, NKA serves as a molecular target for CGs (although it is not the only one) and even though CGs are toxic for humans and some animals, they can also be used as remedies for various diseases, such as cardiovascular ones, and possibly cancer. Although the anticancer mechanism of CGs has not been fully elucidated, yet, it is thought to be connected with the second role of NKA being a receptor that can induce several cell signaling cascades and even serve as a growth factor and, thus, inhibit cancer cell proliferation at low nontoxic concentrations.
    [Show full text]
  • Studies on Myocardial Metabolism. V. the Effects of Lanatoside-C on the Metabolism of the Human Heart
    STUDIES ON MYOCARDIAL METABOLISM. V. THE EFFECTS OF LANATOSIDE-C ON THE METABOLISM OF THE HUMAN HEART J. M. Blain, … , A. Siegel, R. J. Bing J Clin Invest. 1956;35(3):314-321. https://doi.org/10.1172/JCI103280. Research Article Find the latest version: https://jci.me/103280/pdf STUDIES ON MYOCARDIAL METABOLISM. V. THE EFFECTS OF LANATOSIDE-C ON THE METABOLISM OF THE HUMAN HEART 1 By J. M. BLAIN, E. E. EDDLEMAN, A. SIEGEL, AND R. J. BING (From the Departments of Experimental Medicine and Clinical Physiology, The Medical College of Alabama, Birmingham, Alabama, and the Veterans' Administration Hospital, Birmingham, Ala.) (Submitted for publication Septenber 6, 1955; accepted November 16, 1955) Since 1785 when Withering undertook the first this method should aid in elucidating the meta- systemic study of the effects of digitalis, a large bolic pathways within the heart muscle; thus reac- amount of data has been accumulated describing tions determined by more precise in vitro methods its pharmacological effects. Despite intensive could be re-evaluated in the light of data obtained study, the underlying mechanism responsible for on the human heart in vivo. the beneficial results in patients with heart failure The various cardiac glycosides differ in time of remains obscure. Although digitalis in small doses onset and persistence of action. Lanatoside-C, the may affect the heart rate through its vagal effect, preparation used in this study, is a purified deriva- it is agreed that the predominant action of this tive of digitalis lanata which can be given intra- drug is on the heart muscle directly (1).
    [Show full text]
  • Profiling and Structural Analysis of Cardenolides in Two Species of Digitalis Using Liquid Chromatography Coupled with High-Resolution Mass Spectrometry
    bioRxiv preprint doi: https://doi.org/10.1101/864959; this version posted December 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Profiling and structural analysis of cardenolides in two species of Digitalis using liquid chromatography coupled with high-resolution mass spectrometry Baradwaj Gopal Ravi1†, Mary Grace E. Guardian2†, Rebecca Dickman2, Zhen Q. Wang1* 1Department of Biological Sciences, University at Buffalo, State University of New York, Buffalo, NY 14260, United States 2Department of Chemistry, Chemistry Instrumentation Center, University at Buffalo, State University of New York, Buffalo, NY 14260, United States †These authors contributed equally to this work. *Correspondent author: Tel: (+1)7166454969 [email protected] Keywords: cardiac glycoside; foxglove; Digitalis purpurea; Digitalis lanata; digoxin; digitoxin Abstract Plants of the Digitalis genus contain a cocktail of cardenolides commonly prescribed to treat heart failure. Cardenolides in Digitalis extracts have been conventionally quantified by high- performance liquid chromatography yet the lack of structural information compounded with possible co-eluents renders this method insufficient for analyzing cardenolides in plants. The goal of this work is to structurally characterize cardiac glycosides in fresh-leaf extracts using liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) that provides exact masses. Fragmentation of cardenolides is featured by sequential loss of sugar units while the steroid aglycon moieties undergo stepwise elimination of hydroxyl groups, which distinguishes different aglycones. The sequence of elution follows diginatigenindigoxigeningitoxigeningitaloxigenindigitoxigenin for cardenolides with the same sugar units but different aglycones using a reverse-phase column.
    [Show full text]
  • Ouabain - the Insulin of the Heart Hauke Fürstenwerth
    Ouabain - The Insulin of the Heart Hauke Fürstenwerth To cite this version: Hauke Fürstenwerth. Ouabain - The Insulin of the Heart. International Journal of Clinical Practice, Wiley, 2010, 64 (12), pp.1591. 10.1111/j.1742-1241.2010.02395.x. hal-00599542 HAL Id: hal-00599542 https://hal.archives-ouvertes.fr/hal-00599542 Submitted on 10 Jun 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. International Journal of Clinical Practice For PeerOuabain – TheReview Insulin of the HeartOnly Journal: International Journal of Clinical Practice Manuscript ID: IJCP-12-09-0760.R1 Manuscript Type: Perspective Date Submitted by the 18-Jan-2010 Author: Complete List of Authors: Fürstenwerth, Hauke; Hauke Fürstenwerth, consultant Specialty area: International Journal of Clinical Practice Page 1 of 9 International Journal of Clinical Practice 1 2 Title: Ouabain – The Insulin of the Heart 3 4 Author: Dr. Hauke Fürstenwerth 5 6 Unterölbach 3A 7 D-51381 Leverkusen 8 Germany 9 Phone: +49-2171-733740 10 e-mail: [email protected] 11 12 corresponding author: Dr.
    [Show full text]
  • 65: Cardioactive Steroids
    65: Cardioactive Steroids Jason B. Hack HISTORY AND EPIDEMIOLOGY The Ebers Papyrus provides evidence that the Egyptians used plants containing cardioactive steroids (CASs) at least 3000 years ago. However, it was not until 1785, when William Withering wrote the first systemic account about the effects of the foxglove plant, that the use of CASs was more widely accepted into the Western apothecary. Foxglove, the most common source of plant CAS, was initially used as a diuretic and for the treatment of “dropsy” (edema), and Withering eloquently described its “power over the motion of the heart, to a degree yet unobserved in any other medicine.”124 Subsequently, CASs became the mainstay of treatment for congestive heart failure and to control the ventricular response rate in atrial tachydysrhythmias. Because of their narrow therapeutic index and widespread use, both acute and chronic toxicities remain important problems.84 According to the American Association of Poison Control Centers data, between the years 2006 and 2011, there were approximately 8000 exposures to CAS-containing plants with one attributable deaths and about 14,500 exposures to CAS-containing xenobiotics resulting in more than100 deaths (Chap. 136). Pharmaceutically induced CAS toxicity is typically encountered in the United States from digoxin; other internationally available but much less commonly used preparations are digitoxin, ouabain, lanatoside C, deslanoside, and gitalin. Digoxin toxicity most commonly occurs in patients at the extremes of age or those with chronic kidney disease (CKD). In children, most acute overdoses are unintentional by mistakenly ingesting an adult’s medication, or iatrogenic resulting from decimal point dosing errors (digoxin is prescribed in submilligrams, inviting 10-fold dosing calculation errors), or the elderly who are at risk for digoxin toxicity, most commonly from interactions with another medication in their chronic regimen or indirectly as a consequence of an alteration in the absorption or elimination kinetics.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005327 A1 GRANATA Et Al
    US 20090005327A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005327 A1 GRANATA et al. (43) Pub. Date: Jan. 1, 2009 (54) ESSENTIAL, N-3 FATTY ACDS IN CARDAC continuation of application No. 10/451,623, filed on IN SUFFICIENCY AND HEART FAILURE Nov. 21, 2003, now abandoned, filed as application THERAPY No. PCT/EP02/00507 on Jan. 16, 2002. (75) Inventors: Francesco GRANATA, Milan (IT): (30) Foreign Application Priority Data Franco Pamparana, Milan (IT): Eduardo Stragliotto, Milan (IT) Jan. 25, 2001 (IT) .......................... MI2OO1 AOOO129 Correspondence Address: Publication Classification ARENT FOX LLP (51) Int. Cl. 1050 CONNECTICUT AVENUE, N.W., SUITE A6II 3L/202 (2006.01) 400 A63L/704 (2006.01) WASHINGTON, DC 20036 (US) A6IP 9/10 (2006.01) (73) Assignee: PFIZER ITALIA S.R.L., Latina (52) U.S. Cl. ........................................... 514/34: 514/560 (IT) (57) ABSTRACT (21) Appl. No.: 12/207,068 The present invention concerns a method of therapeutic pre vention and treatment of a heart disease chosen from cardiac (22) Filed: Sep. 9, 2008 insufficiency and heart failure including the administration of an essential fatty acid containing a mixture of eicosapen Related U.S. Application Data taenoic acid ethyl ester (EPA) and docosahexaenoic acid (63) Continuation of application No. 1 1/333.387, filed on ethyl ester (DHA), either alone or in combination with Jan. 17, 2006, now Pat. No. 7,439,267, which is a another therapeutic agent. US 2009/0005327 A1 Jan. 1, 2009 ESSENTIALN-3 FATTY ACDS IN CARDAC tensin Converting Enzymes inhibitors), diuretics, non-digi IN SUFFICIENCY AND HEART FAILURE talis positive inotropic drugs such as adrenergics and THERAPY inhibitors of phosphodiesterase, arteriolar and venular vasodilators, e.g.
    [Show full text]
  • Deslanoside | Medchemexpress
    Inhibitors Product Data Sheet Deslanoside • Agonists Cat. No.: HY-A0154 CAS No.: 17598-65-1 Molecular Formula: C₄₇H₇₄O₁₉ • Molecular Weight: 943.08 Screening Libraries Target: Na+/K+ ATPase; Drug Metabolite Pathway: Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 100 mg/mL (106.04 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 1.0604 mL 5.3018 mL 10.6036 mL Stock Solutions 5 mM 0.2121 mL 1.0604 mL 2.1207 mL 10 mM 0.1060 mL 0.5302 mL 1.0604 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution BIOLOGICAL ACTIVITY Description Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations [1][2][3].
    [Show full text]
  • Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer Noel€ J.-M
    Published OnlineFirst December 30, 2015; DOI: 10.1158/0008-5472.CAN-14-2391 Cancer Therapeutics, Targets, and Chemical Biology Research Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer Noel€ J.-M. Raynal1,2, Justin T. Lee1, Youjun Wang3, Annie Beaudry2, Priyanka Madireddi1, Judith Garriga1, Gabriel G. Malouf4, Sarah Dumont4, Elisha J. Dettman4, Vazganush Gharibyan4, Saira Ahmed4, Woonbok Chung1, Wayne E. Childers5, Magid Abou-Gharbia5, Ryan A. Henry6, Andrew J. Andrews6, Jaroslav Jelinek1, Ying Cui7, Stephen B. Baylin7, Donald L. Gill8, and Jean-Pierre J. Issa1 Abstract Targeting epigenetic pathways is a promising approach for prominently cardiac glycosides, did not change DNA methyl- cancer therapy. Here, we report on the unexpected finding that ation locally or histone modifications globally. Instead, all 11 targeting calcium signaling can reverse epigenetic silencing of drugs altered calcium signaling and triggered calcium-calmod- tumor suppressor genes (TSG). In a screen for drugs that ulin kinase (CamK) activity, leading to MeCP2 nuclear exclu- reactivate silenced gene expression in colon cancer cells, we sion. Blocking CamK activity abolished gene reactivation and found three classical epigenetic targeted drugs (DNA methyl- cancer cell killing by these drugs, showing that triggering ation and histone deacetylase inhibitors) and 11 other drugs calcium fluxes is an essential component of their epigenetic that induced methylated and silenced CpG island promoters mechanism of action. Our data identify calcium signaling as a driving a reporter gene (GFP) as well as endogenous TSGs in new pathway that can be targeted to reactivate TSGs in cancer. multiple cancer cell lines. These newly identified drugs, most Cancer Res; 76(6); 1494–505.
    [Show full text]